The IMPrESS study showed that pwMS treated earlier in the course of the disease showed a trend towards lower total (€39,037 vs €42,996), indirect (€15,733 vs €18,934) and disease-modifying therapy (€19,364 vs €20,491) costs and a better health-related quality of life status (0.62 vs 0.56; p < 0.01) compared to those receiving late treatment [ 3 ].
← all excerpts
Economic burden of multiple sclerosis in a population with low physical disability.
1
—
—